Can nivolumab rescue patients when CAR T-Cell therapy fails?
NCT ID NCT04205409
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested nivolumab, an immunotherapy drug, in 20 people with blood cancers like lymphoma, leukemia, or myeloma that came back or didn't respond after CAR T-cell therapy. The goal was to see if nivolumab could help the immune system attack the cancer again. The study measured how many patients responded and how long they lived without the cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab (Opdivo)
- What this could lead to
- If it works, this could offer a new treatment option for people whose blood cancer returns after CAR T-cell therapy.
- What could go wrong
- This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. Nivolumab can cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
- Combination therapy aims to outsmart tough lymphoma
- Targeted drug combo aims to tackle Hard-to-Treat lymphoma
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers